Compare Amylx Pharmaceuticals Inc (AMLX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

Dentsply Sirona (XRAY) trades at $12.26, up 3.11% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $598M in 2025, with negative profit margins and declining revenue trends. Recent news highlights distribution expansion and new AI product launches, while earnings have missed estimates for three consecutive quarters.

The outlook remains challenging with persistent losses and high debt levels, though analyst consensus suggests moderate upside to the $12.50 price target. Key risks include margin pressure and soft European demand, while potential catalysts include digital dentistry adoption and cost management under new CFO leadership.